

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED**

**阿里健康信息技術有限公司**

*(Incorporated in Bermuda with limited liability)*

**(Stock code: 00241)**

### **CLARIFICATION ANNOUNCEMENT UNUSUAL PRICE AND TRADING ANNOUNCEMENT**

The board of directors (the “**Board**”) of Alibaba Health Information Technology Limited (the “**Company**”) has noted the unusual movement in the price and trading volume of the shares of the Company today.

Having made such reasonable enquiry with respect to the Company, the Board confirms that there have been a number of media reports relating to a litigation issued by a pharmacy company in China against the China Food and Drug Administration (the “**CFDA**”) in relation to the drug Product Identification, Authentication and Tracking System (“**Drug PIATS**”), which is owned by the CFDA and operated by the Company.

According to media reports, the pharmacy is alleging that the CFDA’s administrative action of mandatorily implementing the Drug PIATS is unlawful and requesting that the CFDA be ordered to immediately stop such action. Media reports have also reported that a senior official at CFDA indicated that the CFDA will seek to take back operation of the Drug PIATS.

The Company is not a party to the litigation and has not received any notification from the CFDA to cease operation of the Drug PIATS.

As set out in the Company’s public filings, the Board wishes to clarify that the Company is the technical operator of the Drug PIATS and does not own the Drug PIATS as the ownership rights of the Drug PIATS have always belonged to the CFDA. Instead, the Company provides technical support and maintenance services.

The Board confirms that the Company is monitoring the situation very closely, maintains its normal operations and, except for the above, it is not aware of any reasons for such movement in the price and trading volume which must be announced to avoid a false market in the Company’s securities or of any inside information that needs to be disclosed under Part XIVA of the Securities and Futures Ordinance.

This announcement is made by the order of the Company. The Board collectively and individually accepts responsibility for the accuracy of this announcement.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED**  
**WANG Lei**  
*Chief Executive Officer and Executive Director*

Hong Kong, January 28, 2016

*As at the date of this announcement, the Board comprises nine Directors, of which (i) two are executive Directors, namely, Ms. CHEN Xiao Ying and Mr. WANG Lei; (ii) four are non-executive Directors, namely, Mr. WU Yongming, Mr. TSAI Chung, Joseph, Ms. HUANG Aizhu and Mr. KANG Kai; and (iii) three are independent non-executive Directors, namely Mr. YAN Xuan, Mr. LUO Tong and Mr. WONG King On, Samuel.*